Q85.1

Clinical Causes: Genetic mutations in the TSC1 or TSC2 genes, which are responsible for controlling cell growth and division. Inherited from a parent with the disease (about two-thirds of cases are inherited). New mutations in the TSC genes occurring spontaneously (de novo cases).

Key Symptoms: Developmental delays or learning difficulties. Seizures, often starting in early childhood. Skin abnormalities such as facial angiofibromas, hypomelanotic macules (white patches), shagreen patches, and fibrous facial plaques. Benign tumors in the brain, which can cause neurological issues. Growths in the eyes, including retinal hamartomas. Lymphangioleiomyomatosis (LAM), a lung condition that primarily affects women. Kidney issues, such as angiomyolipomas and cysts. Cardiac rhabdomyomas, benign heart tumors that often appear in infancy.

Diagnosis Path: Diagnosis involves a combination of medical evaluations, imaging studies, and genetic testing. It typically includes: - Imaging techniques such as MRI or CT scans to detect tumors in the brain, kidneys, and other organs. - Skin examinations for characteristic skin lesions. - Eye examinations to identify retinal tumors. - Genetic testing to identify mutations in TSC1 or TSC2 genes. - Assessment of developmental milestones and neurological function.

Treatment Protocols: While there is no cure for tuberous sclerosis, various treatments aim to manage symptoms and prevent complications, including: - Antiepileptic medications to control seizures. - Surgical removal or other procedures to treat tumors causing symptoms. - Use of mTOR inhibitors (such as everolimus) to shrink tumors. - Educational and developmental support for learning difficulties. - Regular monitoring of the brain, kidneys, and other organs to detect and address issues early. - Skin treatments to manage lesions, including laser therapy or topical medications. - Multidisciplinary care involving neurologists, dermatologists, nephrologists, and other specialists.